Skip to main content
Clinical Trials/JPRN-UMIN000016728
JPRN-UMIN000016728
Recruiting
Phase 2

Efficacy and safety of nab-paclitaxel plus carboplatin in patients with Carcinoma of unknown primary site - Efficacy and safety of CBDCA plus nab-PTX in patients with CUP

Teikyo University School of Medicine0 sites30 target enrollmentMarch 6, 2015

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Carinoma of unknown primary site(CUP)
Sponsor
Teikyo University School of Medicine
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 6, 2015
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Teikyo University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Indication for radical operation and radiotherapy. 2\)Patients unable to take nab\-paclitaxel and CBDCA because of significant cardiovascular abnormalities, renal dysfunctions, hepatic insufficiency, uncontrolled diabetes, uncontrolled hypertension, bleeding tendency, active interstitial pneumonia,etc. 3\)Known active brain metastasis. 4\)Acute or subacute idiopathic interstitial pneumonia 5\)Patient received a bone\-marrow transplantation 6\)Patient received a peripheral stem cell transplantation 7\)Known hypersensitivity to any drugs 8\)Seropositivity for HBsAg 9\)Pregnancy or breast feeding.

Outcomes

Primary Outcomes

Not specified

Similar Trials